BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18389090)

  • 1. Drospirenone/ethinyl estradiol.
    Rapkin AJ; Sorger SN; Winer SA
    Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone: a novel progestin.
    Rapkin AJ; Winer SA
    Expert Opin Pharmacother; 2007 May; 8(7):989-99. PubMed ID: 17472544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
    J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits.
    Machado RB; Pompei Lde M; Giribela AG; Giribela CG
    Womens Health (Lond); 2011 Jan; 7(1):19-30. PubMed ID: 21175386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
    Dickerson V
    J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein A; Helmerhorst FM
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006586. PubMed ID: 18254106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006586. PubMed ID: 19370644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
    Marr J; Heinemann K; Kunz M; Rapkin A
    Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAZ in the treatment of premenstrual dysphoric disorder.
    Rapkin AJ
    J Reprod Med; 2008 Sep; 53(9 Suppl):729-41. PubMed ID: 18980045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
    Svojanovská K
    Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
    Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
    Krunic A; Ciurea A; Scheman A
    J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
    Bruni Bresciani V
    Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.